KLOW Protocol
Four-Peptide Regenerative Blend | GHK-Cu + TB-500 + BPC-157 + KPV
KLOW is a research peptide combination that builds upon the GLOW protocol by adding KPV for enhanced anti-inflammatory effects. This 80mg blend typically contains 50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, and 10mg KPV in a 5:1:1:1 ratio. While individual components have varying levels of research support, no clinical trials have examined this specific four-peptide combination. The protocol remains investigational with theoretical benefits based on complementary mechanisms.
Daily dose
2-3.2mg total blend
Frequency
Once daily typical
Cycle length
4-6 weeks reported
Storage
2-8°C (refrigerated)
Key benefits
Theoretical synergistic effects from four peptides - tissue repair, anti-inflammation, cellular regeneration
How it works
Each peptide contributes different mechanisms: GHK-Cu modulates genes, TB-500 enhances cell migration, BPC-157 upregulates growth factors, KPV inhibits NF-κB
Dosage protocols
Goal
Common Research Protocol
Dose
3.2mg total (2mg GHK-Cu, 400mcg each TB500/KPV/BPC-157) · Once daily
Route
Subcutaneous
Goal
Starter/Titration Protocol
Dose
2mg total (1.25mg GHK-Cu, 250mcg each TB500/KPV/BPC-157) · Once daily
Route
Subcutaneous
Goal
Cycling Protocol
Dose
As above · 4-6 weeks on, 2-4 weeks off
Route
Subcutaneous
Research indications
wound Healing
recovery
anti Inflammatory
Administration
Interactions
Safety notes
No safety studies on four-peptide combination
Individual peptides generally well-tolerated in research
Injection site reactions common even with KPV
Long-term effects completely unknown
FDA has not approved any component for therapeutic use
Quality and contamination risks in unregulated market
Research studies
Individual Component Research - GHK-Cu (Multiple Studies)
Human studies | Various protocols | 40+ years research
GHK-Cu has extensive research showing wound healing, anti-aging, and gene modulation effects. However, these studies used GHK-Cu alone, not in combination.
BPC-157 Limited Human Data (2020)
Human pilot | 12 patients | Interstitial cystitis
One small pilot study showed 10 of 12 patients achieved complete resolution of interstitial cystitis symptoms. Most BPC-157 research remains in animal models.
No Published Studies on KLOW Combination
No clinical trials | No safety studies | No peer-reviewed research
Despite vendor claims and user reports, no scientific studies have examined the safety or efficacy of the four-peptide KLOW combination.
Two-Peptide Combinations Only (Various)
Limited research | BPC-157 + TB-500 | Animal models
Some research exists on two-peptide combinations like BPC-157 with TB-500, but three and four-peptide combinations lack scientific investigation.